A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study

[1]  J. Vauthey,et al.  Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments. , 2020, Surgical oncology clinics of North America.

[2]  H. Wang,et al.  Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021 , 2020, Journal of hepato-biliary-pancreatic sciences.

[3]  T. Hickish,et al.  Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial , 2020, The Lancet. Oncology.

[4]  W. Scheithauer,et al.  Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Vauthey,et al.  Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation. , 2019, Journal of the American College of Surgeons.

[6]  J. Vauthey,et al.  Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases , 2019, Clinical Cancer Research.

[7]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer , 2019, International Journal of Clinical Oncology.

[8]  Donna Niedzwiecki,et al.  Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Honda,et al.  Comprehensive data of 3,525 patients newly diagnosed with colorectal liver metastasis between 2013 and 2014: 2nd report of a nationwide survey in Japan. , 2018, Journal of hepato-biliary-pancreatic sciences.

[10]  S. Kawasaki,et al.  Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial , 2016, PloS one.

[11]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  C. Verhoef,et al.  The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  K. Hasegawa,et al.  Cetuximab for resectable colorectal liver metastasis: new EPOC trial. , 2014, The Lancet. Oncology.

[14]  T. Hickish,et al.  Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. , 2014, The Lancet. Oncology.

[15]  R. Parks,et al.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.

[16]  M. Makuuchi,et al.  Liver Resection for Multiple Colorectal Liver Metastases with Surgery Up-front Approach: Bi-institutional Analysis of 736 Consecutive Cases , 2012, World Journal of Surgery.

[17]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer , 2012, International Journal of Clinical Oncology.

[18]  G. Honda,et al.  A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery , 2012, Journal of hepato-biliary-pancreatic sciences.

[19]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Curley,et al.  Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases , 2010, Annals of Surgical Oncology.

[21]  R. Labianca,et al.  Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[23]  E. Van Cutsem,et al.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[26]  J. Bosset,et al.  Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Pawlik,et al.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[29]  F. Lévi,et al.  Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.

[30]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[31]  S. Lipsitz,et al.  Abstracts reprinted from Journal of Clinical Oncology , 2002, Annals of Surgical Oncology.

[32]  L H Blumgart,et al.  Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. , 1999, The New England journal of medicine.

[33]  W. Bechstein,et al.  Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen) , 1998, Annals of surgery.

[34]  J. Weitz,et al.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.